CLDN20

Across TCGA pan-cancer cohorts, CLDN20 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated CLDN20 data layer compared with 2 for mutation status.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher CLDN20 RNA is associated with better overall survival. In most high-consensus cancer types, elevated CLDN20 expression acts as an unfavorable survival marker, although some lineages such as READ and LUSC show a favorable association.

READ, LUSC, and UCS are the cancer types where CLDN20 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	All	0.839	0.317	<.001	54	view →
LUSC	OS	Quartile	II,III,IV	0.815	0.642	.006	36	view →
UCS	DFS	Median	IV	0.952	0.367	.001	36	view →
LGG	OS	Tertile	All	0.329	0.531	<.001	34	view →
SCLC	OS	Tertile	II,III,IV	0.820	0.516	.010	28	view →
OV	DFS	Quartile	IV	0.319	0.614	.011	18	view →
STAD	DFS	Tertile	III,IV	0.461	0.689	.011	17	view →
COAD	DFS	Tertile	II,III,IV	0.201	0.596	<.001	17	view →
THCA	OS	Tertile	II,III,IV	0.967	1.000	.022	14	view →
UVM	OS	Quartile	III,IV	0.414	1.000	.016	9	view →
HNSC	OS	Median	IV	0.411	0.317	.023	8	view →
UCEC	DFS	Median	III,IV	0.671	0.471	.037	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

CLDN20–READ (OS)

Open the READ breakdown →